CCK2R (CCKBR) as a Radioligand Therapy Target
CCK2R (CCKBR), cholecystokinin B receptor, is a cell-surface protein (GPCR). No tumor protein staining is recorded for it in Human Protein Atlas immunohistochemistry. Evidence on whether CCK2R internalizes is mixed. Clinical status: Clinical-stage (up to phase 2, any modality).
Is CCK2R a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ❌ Tumor expression: No tumor staining in HPA immunohistochemistry.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CCK2R expression in cancer
No Human Protein Atlas tumor immunohistochemistry data is available for CCK2R.
Is CCK2R internalized?
Uncertain. Insufficient literature found.
Sources: PMID 34994328 · PMID 33198403 · PMID 33042258 · PMID 23275470 · PMID 17088981. AI-extracted from abstracts, so verify before citing.
CCK2R clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for CCK2R yet. Search ClinicalTrials.gov for CCK2R trials.
CCK2R normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CCK2R in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CCK2R gene essentiality (DepMap)
CRISPR knockout effect across 1226 cancer cell lines: 0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
See how CCK2R ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.